Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Urine Test Stratifies Prostate Cancer Risk

By LabMedica International staff writers
Posted on 30 Aug 2011
A urine test based on biomarkers may soon be available to aid in the early detection and treatment of prostate cancer.

A novel urine test has been designed to identify two genetic markers that are known to be present in prostate cancer patients complementing the Prostate Specific Antigen (PSA) test. More...


Scientists working in the University of Michigan Health System (Ann Arbor, MI, USA) have developed a urinary screening test for prostate cancer based on two biomarkers. These biomarkers, are the fusion transmembrane protease serine 2: Ets Related Gene (TMPRSS2:ERG) and the prostate cancer gene 3 (PCA3), both are known to be present in prostate cancer patients. This TMPRSS:ERG gene was demonstrated to be upregulated by androgenic hormones in prostate cancer cells and downregulated in androgen-independent prostate cancer tissue. PCA3 is a gene, which has noncoding messenger ribonucleic acid (mRNA) that is overexpressed in prostate cancer and is useful as a tumor marker.

The study looked at 1,312 men with elevated PSA levels and subsequent prostate removals, comparing the results of their urine tests with those of their biopsies. The investigators believe that the correlations they found in the two test results indicate that the urine test will be an effective tool in detecting a man's prostate cancer risk. Because TMPRSS2:ERG is caused by two genes switching places and then fusing together, is believed by some to be the cause of prostate cancer, but it only occurs in approximately half of cancer patients. Therefore, screening for the second genetic marker, PCA3, is included in the urine test.

The urine test is a product of Gen-Probe (San Diego, CA, USA), and although the urine test has not yet been submitted to the authorities for approval nor is it available to the public, the University of Michigan will soon begin using it. David B. Samadi, MD, from Mount Sinai Medical Center (New York, NY, USA), said, "Studies of these two genetic markers have been performed in the past, and there is evidence that combining such a test with the PSA blood test may result in a better prediction of prostate cancer."

Related Links:
University of Michigan Health System
Gen-Probe
The Mount Sinai Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.